Halozyme Therapeutics (HALO): A Momentum Stock to Consider

Halozyme Therapeutics (HALO) is a biopharmaceutical company with a Momentum Style Score of A and VGM Score of A. Its shares have seen a 2.8% increase in the last one week and a 3.8% gain in the last one year. The company has a Zacks Rank of #3 (Hold) and boasts an average earnings surprise of 17.6%. HALO's solid earnings metrics and impressive momentum and VGM style scores make it a potential addition to investors' portfolios.